Previous clinical studies have confirmed that revascularization or recanalization rate after intravenous thrombolysis is closely related to the formation of thrombus, which also results in poor neurological function after thrombolysis. Platelet activating factor (PAF) strong platelet aggregation may be involved in thrombosis. Formation process. The main components of Ginkgolide injection (Ginkgo) are ginkgolide, ginkgolides A, ginkgolides B and ginkgolides C. Ginkgo biloba lactone can antagonize PAF and has strong anti-platelet aggregation. . Therefore, it can be speculated that ginkgolides injection combined with alteplase intravenous thrombolysis may improve the recanalization rate after thrombolysis and reduce the reocclusion rate.
In addition, clinical studies have also found that ginkgolide injection has a good auxiliary effect on hypertensive intracerebral hemorrhage, which can regulate inflammatory factors such as IL-6, TNF-α and high-sensitivity C-reactive protein (CRP) in patients. Recovery of neurological function in patients. It is well known that TNF-α, IL-β, IL-1, IL-6, IFN-γ, etc. are all inflammatory factors associated with reperfusion injury. Therefore, we speculate that ginkgolides injection may also regulate inflammatory factors associated with reperfusion injury, such as IL-6, TNF-α, thereby reducing reperfusion injury, thereby improving patient prognosis.
The aim of this study was to determine the clinical efficacy of ginkgolides injection combined with alteplase in the treatment of acute ischemic stroke, and to improve the prognosis of patients with thrombolysis.

开始日期2018-07-31

申办/合作机构

浙江大学医学院附属第二医院

[+3]

CTR20132020 / Completed临床4期

银杏内酯注射液治疗缺血性脑卒中（恢复期），瘀血阻络证非对照、开放式、多中心临床研究

1.评价银杏内酯注射液用于缺血性脑卒中、瘀血阻络证的安全性； 2.评价银杏内酯注射液不良反应发生的相关因素。

开始日期2013-06-06

申办/合作机构

四川三民药业有限公司

[+2]

100 项与银杏内酯注射液相关的临床结果

登录后查看更多信息

100 项与银杏内酯注射液相关的转化医学

登录后查看更多信息

100 项与银杏内酯注射液相关的专利（医药）

登录后查看更多信息

514

项与银杏内酯注射液相关的文献（医药）

2024-12-01·International Immunopharmacology

Ginkgolide A enhances FoxO1 expression and reduces endoplasmic reticulum stress to mitigate osteoarthritis in mice

Article

作者: Chen, Kaiye ; Chen, Hao ; Lin, Zhongke ; Gou, Yong ; Yu, Heng ; Li, Xiang ; Lu, Keyu ; Bao, Yingying ; Jin, Yangcan ; Liang, Jinghao

This study aimed to investigate the effects of Ginkgolide A (GA) on chondrocytes under oxidative stress and to elucidate its potential molecular mechanisms. Using a destabilization of the medial meniscus (DMM) model in mice and an in vitro osteoarthritis (OA) model induced by tert-butyl hydroperoxide (TBHP) in chondrocytes, we validated the therapeutic efficacy and underlying mechanisms of GA. Potential OA targets of GA were identified through network pharmacology, Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Further exploration into the effects on endoplasmic reticulum stress (ERS), apoptosis, extracellular matrix (ECM) degradation, and Forkhead Box O1 (FoxO1) related pathways was conducted using Western blotting, immunofluorescence, TUNEL staining, flow cytometry, X-ray, micro-computed tomography (Micro-CT) analysis, and histological staining. The results demonstrated that GA upregulated FoxO1 expression and inhibited ERS-related signaling pathways, thereby reducing apoptosis and ECM degradation. In conclusion, GA significantly alleviated OA symptoms both in vitro and in vivo, suggesting its potential as a therapeutic agent for OA.

2024-11-01·Redox Biology

Activation of nuclear receptor pregnane-X-receptor protects against abdominal aortic aneurysm by inhibiting oxidative stress

Article

作者: Fang, Peiliang ; Yuan, Ancai ; Shen, Zhi ; Chen, Alex F. ; Wang, Jinxi ; Chen, Yifei ; Chen, Alex F ; Lyu, Yuyan ; Pu, Jun ; Yan, Xiaoxiang

Abdominal aortic aneurysm (AAA) is a life-threatening condition, but effective medications to prevent its progression and rupture are currently lacking. The nuclear receptor pregnane-X-receptor (PXR) plays a crucial role in vascular homeostasis. However, the role of PXR in AAA development remains unknown. We first detected the PXR expression in human and murine AAA tissues by RT-qPCR and Western blot. To investigate the potential role of PXR in the development of AAA, we used adeno-associated virus-mediated overexpression of PXR and pharmacological activation of PXR by ginkgolide A (GA) in mouse AAA models induced by both angiotensin II (AngII) and calcium phosphate [Ca₃(PO₄)₂]. The underlying mechanism was further explored using RNA-sequencing and molecular biological analyses. We found a significant decrease in both mRNA and protein levels of PXR in both human and murine aortic smooth muscle cells from AAA tissues, accompanied with phenotypic switching of vascular smooth muscle cell and increased oxidative stress. PXR overexpression in abdominal aortas and GA treatment successfully suppressed AAA formation in both mouse AAA models. RNA-sequencing data revealed that PXR activation inhibited gamma-aminobutyric acid type A receptor subunit alpha3 (GABRA3) expression. Additional mechanistic studies identified that PXR suppressed AAA through mitigating GABRA3-induced reactive oxygen species (ROS) generation and subsequent phosphorylation of c-Jun N-terminal kinase (JNK). Interestingly, p-JNK was found to induce ubiquitin-proteasome degradation of PXR. In summary, our data unveiled, for the first time, the protective role of PXR against AAA pathogenesis by inhibiting oxidative stress. These findings suggested PXR as a promising therapeutic target for AAA.

2024-10-09·Journal of Agricultural and Food Chemistry

Orally Administered Ginkgolide C Alleviates MPTP-Induced Neurodegeneration by Suppressing Neuroinflammation and Oxidative Stress through Microbiota–Gut–Brain Axis in Mice

Article

作者: Gao, Xiyu ; Yan, Aohan ; He, Dewei ; Yang, Shuo ; Zhang, Yiming ; Liu, Dianfeng ; Fu, Shoupeng ; Wen, Jingru

Parkinson's disease (PD) is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra, the etiology of which remains unclear. Studies have shown that neuroinflammation and oxidative stress (OS) play an important role in neuronal damage in patients with PD. Disturbances in the gut microbiota influence neuroinflammation and OS through the microbiota-gut-brain axis. Ginkgolide C (GC), a traditional Chinese medicine extracted from the leaves of Ginkgo biloba, has been reported to exhibit anti-inflammatory effects and the ability to modulate intestinal microbial composition. However, the potential of GC to positively impact PD by modulating the gut microbiota remains unexplored. This study aimed to explore the effects of GC on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD in mice and elucidate its underlying mechanisms. Our findings elucidated that GC treatment significantly ameliorates behavioral deficits as well as pathological damage via restoring gut microbial homeostasis to downgrade OS and neuroinflammation in MPTP-induced PD mice. Mechanistically, GC treatment exerts antioxidant effects via activating the AKT/Nrf2/HO-1 pathway in MPP⁺-exposed SN4741 neuronal cells and significantly downregulates the expression of inflammatory mediators via regulating NF-κB and MAPK signaling in lipopolysaccharide (LPS)-stimulated BV2 microglial cells. Overall, our study demonstrates that GC administration alleviates MPTP-induced neurodegeneration via rebuilding gut microbial homeostasis to inhibit OS and neuroinflammation in mice, indicating that GC might serve as a promising candidate medicine for PD.

项与银杏内酯注射液相关的新闻（医药）

2024-10-19

·精准药物

刚刚，国产肿瘤小分子11.7亿美元：授权MNC

2024年10月16日，百裕制药与诺华就一款小分子抗肿瘤药物签订独家许可协议。笔者推测是DNA-PK。 -根据协议，百裕将收到7000万美元首付款，以及可达11亿美元的开发、注册及商业化等各类里程碑付款和相应特许使用费。-诺华将获得该款小分子创新药的全球独家开发及商业化权利。-这次战略合作是百裕向全球患者提供潜在抗肿瘤药物重要一步，期待积极成果实现。百裕制药总部位于中国成都，专注于药物发明发现，多次荣获国家奖项，专注银杏核心药效成分研究二十余年，成功开发现代植物药（银杏叶有效部位制剂）“银杏内酯注射液”及“银杏总内酯滴丸”。 Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor CHENGDU, Oct.16th, 2024 -- Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset. Under the terms of the license agreement, Baiyu will receive an upfront payment of $70 million and is eligible to receive additional development, regulatory and commercial milestones payments of up to $1.1 billion, as well as tiered royalties. Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset. This collaboration is an important step for Baiyu in making potential anti-tumor drugs available to patients globally, and Baiyu look forward to positive results being realized. About Chengdu Baiyu Biopharmaceutical Co., Ltd. Founded in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu, China. The company is dedicated to discover and develop innovative medicines, for which it has earned numerous prestigious national awards. With over 20 years of focused research on the core pharmacological components of Ginkgo biloba, we have successfully developed modern botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping Pills. 声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

引进/卖出

2024-10-18

·PipelineReview

Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. (“Baiyu”) today announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset. Under the terms of the license agreement, Baiyu will receive an upfront payment of $70 million and is eligible to receive additional development, regulatory and commercial milestones payments of up to $1.1 billion, as well as tiered royalties. Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset. BFC Group acted as the exclusive financial advisor to Baiyu. This collaboration is an important step for Baiyu in making potential anti-tumor drugs available to patients globally, and Baiyu look forward to positive results being realized. About Chengdu Baiyu Biopharmaceutical Co., Ltd. Founded in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu, China. The company is dedicated to discover and develop innovative medicines, for which it has earned numerous prestigious national awards. With over 20 years of focused research on the core pharmacological components of Ginkgo biloba, we have successfully developed modern botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping Pills. SOURCE: Chengdu Baiyu Biopharmaceutical

引进/卖出

2024-10-17

·药渡

百裕制药与诺华签订一款在研抗肿瘤小分子药物的独家许可协议

2024年10月16日，百裕制药与诺华就一款小分子抗肿瘤药物签订独家许可协议。根据协议，百裕将收到7000万美元首付款，以及可达11亿美元的开发、注册及商业化等各类里程碑付款和相应特许使用费。诺华将获得该款小分子创新药的全球独家开发及商业化权利。 BFC Group在本次交易中担任百裕制药独家财务顾问。这次战略合作是百裕向全球患者提供潜在抗肿瘤药物重要一步，期待积极成果实现。关于百裕百裕制药总部位于中国成都医学城，专注于药物发明发现，多次荣获国家奖项，专注银杏核心药效成分研究二十余年，成功开发现代植物药（银杏叶有效部位制剂）“银杏内酯注射液”及“银杏总内酯滴丸”。 Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor Baiyu to receive $70 million upfront, with potential for up to $1.1 billion in development, regulatory and commercial milestones as well as tiered royalties. CHENGDU, Oct.16th, 2024-- Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset. Under the terms of the license agreement, Baiyu will receive an upfront payment of $70 million and is eligible to receive additional development, regulatory and commercial milestones payments of up to $1.1 billion, as well as tiered royalties. Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset. BFC Group acted as the exclusive financial advisor to Baiyu. This collaboration is an important step for Baiyu in making potential anti-tumor drugs available to patients globally, and Baiyu look forward to positive results being realized. About Chengdu Baiyu Biopharmaceutical Co., Ltd. Founded in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu, China. The company is dedicated to discover and develop innovative medicines, for which it has earned numerous prestigious national awards. With over 20 years of focused research on the core pharmacological components of Ginkgo biloba, we have successfully developed modern botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping Pills.

引进/卖出

100 项与银杏内酯注射液相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑梗塞	中国	成都百裕制药股份有限公司	2011-10-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03772847 (GIANT, Pubmed)	临床4期	急性缺血性卒中	1,113	Ginkgolide®	遞積齋憲選醖鹹衊鏇範(築鹽鏇艱廠憲範鬱憲壓) = 壓製鏇製鏇鏇觸範願鹽膚願壓膚衊網鏇鬱製廠 (醖選廠構鏇壓壓鑰遞製 )	-	2021-01-01